Aesyra, a medical device company pioneering oral appliance technologies to improve sleep, today announced it has raised $3 million in seed financing. The round was led by Supermoon Capital (USA), the world’s first fund focused on sleeptech, and deep tech investor Creadd Ventures (Switzerland) with participation from existing investor Zürcher Kantonalbank.
The new financing will support the development and commercialization of Aesyra’s AesyBite® line of products for accurate monitoring and treatment of sleep bruxism and sleep apnea. Sleep bruxism is a sleep disorder often linked to sleep apnea, which affects nearly a billion people worldwide. A spin-off of the Federal Institute of Technology of Lausanne (EPFL) in Switzerland, Aesyra has pioneered a powerful technology system — that combines a unique oral appliance device, proprietary sensors, and AI — that has demonstrated over 70% reduction of bruxism activity for users. Powering Aesyra’s AesyBite™ are technology developed by EPFL researchers and algorithms that leverage over 10 years of sleep research data.
“Aesyra’s advanced technology is a tremendous breakthrough in the field of sleep science for the treatment of sleep bruxism and sleep apnea”
Fintech Insights: Hyper-personalization in Banking: The Tech Journey to Serving a Segment of One
“This significant investment marks a pivotal moment for Aesyra,” said Marco Letizia, founder and CEO of Aesyra. “We are thrilled to partner with Supermoon Capital and Creadd Ventures, who share our vision of driving meaningful change within the sleep industry. With their support, we are well-positioned to accelerate the deployment of our groundbreaking solutions, ultimately improving patient outcomes and advancing healthcare practices.”
“Aesyra’s advanced technology is a tremendous breakthrough in the field of sleep science for the treatment of sleep bruxism and sleep apnea,” said Michael Masterson, Managing Partner at Supermoon Capital “We are impressed by the company’s unique approach, strong leadership team and unwavering commitment to revolutionize healthcare, and we are looking forward to working closely with Aesyra to support its mission.”
“We selected Aesyra as the first investment of Creadd Ventures since it perfectly fits our philosophy to invest in companies that have the potential to make a profound impact on the quality of life of patients,” said Lorenzo Leoni, Founder and Managing Partner at Creadd Ventures.
Masterson Leoni will join the Board of Directors of Aesyra, bringing their extensive industry expertise and strategic guidance to accelerate the company’s growth and success.
Read More About Fintech Interviews: How Blockchain-Powered Ecosystems Are Poised to Transform the Agricultural Sector
[To share your insights with us, please write to pghosh@itechseries.com ]
